Cutting Edge Information, May 2009, Pages: 104
of companies with investigator compensation limits in place
-Average number of total site fees by phase
-Average number of investigators per site, by phase
Investigator Compensation By Therapeutic Area
Cutting Edge Information, Sep 2009, Pages: 219
ROI. Our data benchmarks - developed from input from marketing executives, brand managers, speaker programs directors among others - will anchor your decisions. The report will help you build a clear
Cutting Edge Information, Dec 2007, Pages: 151
Compensation 92
Figure 2.10: High Performing Primary Care Rep Compensation 93
Figure 2.11: Bonus Compensation as a % of Total Pay: Average Primary Care Rep 94
Figure 2.12: New Hire Specialty/Hospital Rep
Cutting Edge Information, April 2009, Pages: 141
- Maximizing Sales Rep Success
Structures, Budgets and Sales Staff Compensation
- Sales Force Contraction Data
- Sales Force Investments
- Sales Staff CompensationExecutive Summary
LIST OF FIGURES
Cutting Edge Information, Oct 2011, Pages: 128
The latest report from Cutting Edge Information will enable readers to develop HOL capabilities and reach payers via optimal team alignment and structure, competitive compensation and a strong slate
Plunkett Research, Ltd, Nov 2011, Pages: 714
.S.: 2002-2010
12) Employers' Costs for Health Insurance, Amount & Percent of TotalCompensation, U.S.: Selected Years, 2006-2010
13) Life Expectancy at Age 65, U.S., Selected Years
14) Overweight & Obesity
CYGNUS Business Consulting & Research, March 2008, Pages: 143
will not be feasible unless the demand can compensate for the low margins. Global vaccines market is estimated at USD10 billion in 2007; human vaccine valued at USD8.3 billion contributes major share ie 83% of the total
Datamonitor, Nov 2010, Pages: 244
R&D and manufacturing
M&A activity
7. China - Bibliography
China - Executive summary
Publications and online articles
Datamonitor reports and products
China - Socio-demographic and Economic
Markets and Markets, May 2011, Pages: 417
The targeted audience for this report includes:
- Pharmaceutical and biotech companies
- Medical devices manufacturers
- Pharma-research labs
- Doctors, physicians, and hospitals
- Medical/Pharma
Datamonitor, Dec 2008, Pages: 267
such as Wyeths Prevnar or Merck & Cos Gardasil, along with the emergence of novel vaccine technologies and favourable legislation have brought vaccines back into the main focus of pharmaceutical and biotech
ICON Group International, June 2007, Pages: 394
Accessibility In the top figure, the firm is driven by market potential, whereas the bottom figure represents a firm that is driven by costs or by an aversion to difficult markets. This report treats the reader
ICON Group International, June 2007, Pages: 386
Relative Accessibility In the top figure, the firm is driven by market potential, whereas the bottom figure represents a firm that is driven by costs or by an aversion to difficult markets. This report
